ATC Group: L01AX03 Temozolomide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01AX03 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01A Alkylating agents
4 L01AX Other alkylating agents
5 L01AX03 Temozolomide

Active ingredients in L01AX03

Active Ingredient Description
Temozolomide

Temozolomide is a triazene, which undergoes rapid chemical conversion at physiologic pH to the active monomethyl triazenoimidazole carboxamide (MTIC). The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position. Cytotoxic lesions that develop subsequently are thought to involve aberrant repair of the methyl adduct.

Related product monographs

Title Information Source Document Type  
TEMODAL Hard capsule European Medicines Agency (EU) MPI, EU: SmPC
TEMODAL Powder for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Albania (AL)

Australia (AU)

Austria (AT)

Canada (CA)

Croatia (HR)

Estonia (EE)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.